FDA recall Z-2225-2021

BioMerieux SA · Class II · device

Product

MYLA software. Used to manage microbiology test workflow from the reception of requests to the transmission of results by transferring, storing, and displaying medical device data.

Reason for recall

Software anomaly - Under certain conditions, unwanted alterations to results could be applied when using the BCI Connect scripting feature.

Distribution

Distribution in the U.S. was nationwide. There was also military and government distribution.

Key facts

Status
Terminated
Initiation date
2021-06-22
Report date
2021-08-18
Termination date
2023-02-06
Voluntary/Mandated
Voluntary: Firm initiated
Location
Marcy L'Etoile, N/A, France

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-2225-2021